Post-Exablate Pregnancy Outcomes Registry Study for Uterine Fibroids
This study is an observational registry looking at pregnancy outcomes in women who have received Exablate treatment for symptomatic uterine fibroids (non-cancerous growths in the uterus). The Exablate system uses MR-Guided Focused Ultrasound (a non-invasive procedure that uses sound waves to treat fibroids). The goal is to collect information on how Exablate treatment affects potential pregnancies for two years after treatment. This information will help update labeling and gather overall safety data. You may be able to join if you are a woman between 18 and 50 years old who has received Exablate treatment for symptomatic fibroids. The study aims to enroll 200 participants.
- Study design
- This is an observational study with a planned enrollment of 200 women.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through study completion, an average of 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
At a glance
Conditions
NCT05386615
Where you'd take part
This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic
Rochester, Minnesotastudy coordinator listed
Recruiting
Shanghai No. 1 Hospital
Shanghai, Chinastudy coordinator listed
Recruiting
Shanghai No.1 Hospital
Shanghai, Chinastudy coordinator listed
Recruiting
Stanford University
Stanford, Californiastudy coordinator listed
Recruiting
UCLA
Los Angeles, Californiastudy coordinator listed
Recruiting
Huashan Hospital Affiliated to Fudan University
Shanghai, Chinano site contact published
Active, not recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Occurrence of adverse eventsThrough study completion, an average of 2 years.
All adverse events and/or serious adverse events will be documented and reported according to protocol.